- Home
- NRC vs AKBA Comparison
NRC vs AKBA Comparison
Compare NRC & AKBA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NRC
- AKBA
- Stock Information
- Founded
- NRC 1981
- AKBA 2007
- Country
- NRC United States
- AKBA United States
- Employees
- NRC N/A
- AKBA N/A
- Industry
- NRC Biotechnology: Commercial Physical & Biological Resarch
- AKBA Biotechnology: Pharmaceutical Preparations
- Sector
- NRC Health Care
- AKBA Health Care
- Exchange
- NRC Nasdaq
- AKBA Nasdaq
- Market Cap
- NRC 394.2M
- AKBA 336.2M
- IPO Year
- NRC N/A
- AKBA 2014
- Fundamental
- Price
- NRC $17.82
- AKBA $2.37
- Analyst Decision
- NRC
- AKBA Strong Buy
- Analyst Count
- NRC 0
- AKBA 1
- Target Price
- NRC N/A
- AKBA $7.50
- AVG Volume (30 Days)
- NRC 89.4K
- AKBA 2.4M
- Earning Date
- NRC 02-11-2025
- AKBA 03-13-2025
- Dividend Yield
- NRC 2.67%
- AKBA N/A
- EPS Growth
- NRC N/A
- AKBA N/A
- EPS
- NRC 1.12
- AKBA N/A
- Revenue
- NRC $144,155,000.00
- AKBA $169,879,000.00
- Revenue This Year
- NRC N/A
- AKBA N/A
- Revenue Next Year
- NRC N/A
- AKBA $30.85
- P/E Ratio
- NRC $15.51
- AKBA N/A
- Revenue Growth
- NRC N/A
- AKBA N/A
- 52 Week Low
- NRC $16.50
- AKBA $0.80
- 52 Week High
- NRC $42.00
- AKBA $2.48
- Technical
- Relative Strength Index (RSI)
- NRC 51.30
- AKBA 75.15
- Support Level
- NRC $16.79
- AKBA $1.72
- Resistance Level
- NRC $17.47
- AKBA $2.00
- Average True Range (ATR)
- NRC 0.69
- AKBA 0.11
- MACD
- NRC 0.09
- AKBA 0.04
- Stochastic Oscillator
- NRC 67.69
- AKBA 100.00
About NRC National Research Corporation (Delaware)
National Research Corp is a provider of analytics and insights that facilitate measurement and improvement of the patient and employee experience while also increasing patient engagement and customer loyalty for healthcare providers, payers, and other healthcare organizations. Its portfolio of solutions represents a set of capabilities that individually and collectively provide value to clients. It operates in the United States and Canada, of which key revenue is derived from the United States.
About AKBA Akebia Therapeutics Inc.
Akebia Therapeutics Inc is a fully integrated biopharmaceutical company. The Company's operating segment is the business of developing and commercializing novel therapeutics for people with kidney disease. The current portfolio of the company includes Auryxia (ferric citrate), a medicine approved and marketed in the United States for the control of serum phosphorus levels in adult patients with dialysis-dependent chronic kidney disease and the treatment of iron deficiency anemia, in adult patients with non-dialysis-dependent chronic kidney disease, Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, inhibitor, is approved in Japan for the treatment of anemia due to chronic kidney disease, in adult patients, HIF-PH inhibitors in preclinical development.